2-氯-3-三氟甲基苯硼酸 | 957061-11-9

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3-三氟甲基苯硼酸
• 中文别名: 2-氯-6-三氟甲基苯硼酸；2-氯-3-(三氟甲基)苯硼酸
• 英文名称: 2-chloro-3-(trifluoromethyl)phenylboronic acid
• 英文别名: [2-chloro-3-(trifluoromethyl)phenyl]boronic acid
• CAS: 957061-11-9
• 化学式: C₇H₅BClF₃O₂
• mdl: MFCD09258745
• 分子量: 224.375
• InChiKey: NEHJDQKHVZYUAA-UHFFFAOYSA-N

物化性质

• 沸点：
  313.5±52.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.04
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-3-(trifluoromethyl)phenylboronic acid
Synonyms: 2-Chloro-3-trifluoromethylphenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-3-(trifluoromethyl)phenylboronic acid
CAS number: 957061-11-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BClF3O2
Molecular weight: 224.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-三氟甲基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-溴代丁二酰亚胺(NBS) 、 氢溴酸 、 palladium diacetate 、 sodium carbonate 、 caesium carbonate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.42h， 生成 3-[[2-[2-Chloro-3-(trifluoromethyl)phenyl]-4-oxo-5-pyrrolidin-1-ylpyridin-1-yl]methyl]benzonitrile
  参考文献：
  名称：

  NITROGEN-CONTAINING SIX-MEMBERED CYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

  摘要：

  化合物的化学式为(I)：其中Z1为C(R2)或N；Z3为CH或N；Z2为C(R3)或N；前提是当Z2为N时，Z1为C(R2)且Z3为CH；环A为取代或未取代的芳香族碳环，或类似物；R1为取代或未取代的烷基，或类似物；R2为氢原子、卤素或类似物；R3为氢原子、卤素或类似物；或其药学上可接受的盐。

  公开号：

  US20160318916A1

文献信息

• Design, Synthesis and Biological Evaluation of Arylpyridin-2-yl Guanidine Derivatives and Cyclic Mimetics as Novel MSK1 Inhibitors. An Application in an Asthma Model
  作者：Maud Bollenbach、Simona Nemska、Patrick Wagner、Guillaume Camelin、François Daubeuf、Adeline Obrecht、Pascal Villa、Didier Rognan、Frédéric Bihel、Jean-Jacques Bourguignon、Martine Schmitt、Nelly Frossard

  DOI：10.3390/molecules26020391

  日期：——

  psoriasis and atherosclerosis. To date, few MSK1 inhibitors were reported. In order to identify new MSK1 inhibitors, a screening of a library of low molecular weight compounds was performed, and the results highlighted the 6-phenylpyridin-2-yl guanidine (compound 1a, IC50~18 µM) as a starting hit for structure-activity relationship study. Derivatives, homologues and rigid mimetics of 1a were designed

  丝裂原和应激激活激酶 1 (MSK1) 是一种核激酶，参与促炎转录因子 NF-kB 的激活途径，并在哮喘、银屑病和动脉粥样硬化等炎症性疾病中显示出治疗靶点的潜力。迄今为止，很少报道 MSK1 抑制剂。为了鉴定新的 MSK1 抑制剂，对低分子量化合物库进行了筛选，结果突出显示 6-苯基吡啶-2-基胍（化合物 1a，IC50~18 µM）作为结构的起始命中 -活动关系研究。设计了 1a 的衍生物、同系物和刚性模拟物，并评估了所有合成化合物对 MSK1 的抑制活性。其中，无细胞毒性的 2-氨基苯并咪唑 49d 在显着抑制方面最有效：
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE LA DOULEUR
  申请人：UNIV STRASBOURG

  公开号：WO2019149965A1

  公开（公告）日：2019-08-08

  The invention relates to compounds, pyridine derivatives, and pharmaceutical 10 compositions containing same for use in the treatment of pain. It also relates to specific compounds, compositions comprising the same and uses thereof, in particular in the treatment of pain.

  这项发明涉及化合物、吡啶衍生物和含有这些化合物的药物组合物，用于治疗疼痛。它还涉及特定化合物、包含这些化合物的组合物及其用途，特别是在疼痛治疗中的应用。
• SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Vernhet Claude

  公开号：US20110144115A1

  公开（公告）日：2011-06-16

  The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CB 2 receptors, their preparation and their therapeutic application.

  本发明涉及具有与大麻素CB2受体亲和力的新型取代1-苄基香豆素-4(1H)-酮衍生物，其制备和治疗应用。
• SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME
  申请人：Barbagallo Elodie

  公开号：US20120129864A1

  公开（公告）日：2012-05-24

  The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C 2 -C 5 )alkylene radical which is unsubstituted or substituted one or more times by an Alk group; R 1 represents a phenyl, a naphthyl, a pyridyl, a 1-benzothienyl or a 1,3-benzodioxolyl; R 2 represents a hydrogen atom, a halogen atom, an Alk group, an OAlk group or else a group chosen from —S-Alk, —SO-Alk, —SO 2 -Alk, —CO—N(R 4 )-Alk, —N(R 4 )SO 2 -Alk, —N(R 4 )CO-Alk, —N(R 4 )SO 2 —N(Alk) 2 ; R 3 represents a hydrogen atom, a halogen atom, an Alk group or an OAlk group; R 4 represents a hydrogen atom or a (C 1 -C 4 )alkyl; Alk represents an unsubstituted or substituted (C 1 -C 4 )alkyl. Preparation process and therapeutic application.

  本发明的主题是符合以下式（I）的化合物：其中：X代表未取代或通过一个或多个Alk基团取代的二价（C2-C5）烷基基团；R1代表苯基、萘基、吡啶基、1-苯并噻吩基或1,3-苯并二噁唑基；R2代表氢原子、卤原子、Alk基团、OAlk基团或从中选择的一种基团，包括—S-Alk、—SO-Alk、—SO2-Alk、—CO—N（R4）-Alk、—N（R4）SO2-Alk、—N（R4）CO-Alk、—N（R4）SO2—N（Alk）2；R3代表氢原子、卤原子、Alk基团或OAlk基团；R4代表氢原子或（C1-C4）烷基；Alk代表未取代或取代的（C1-C4）烷基。制备过程和治疗应用。
• Polycyclic compounds as lysophosphatidic acid receptor antagonists
  申请人：Clark Ryan

  公开号：US08778983B2

  公开（公告）日：2014-07-15

  Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

  本文描述了一些能够拮抗溶血磷脂酸受体的化合物。同时，还描述了包括这些化合物的药物组合物和药物，以及使用这些拮抗剂的方法，单独或与其他化合物结合，用于治疗LPA依赖性或LPA介导的疾病或症状。